Isradipine

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

伊拉地平是一种有效的选择性 L 型电压门控钙通道阻滞剂，用于治疗高血压。

Isradipine is a potent and selective L-type voltage-gated calcium channel blocker, used to treat high blood pressure.(In Vitro):Isradipine has much higher (＞40 fold) affinity for Cav1.3 channels as well as good brain bioavailability. Isradipine has nearly equal potency at Cav1.2 and Cav1.3 channels.(In Vivo):Isradipine (0.1~3 mg/kg; p.o.) makes sodium excretion increase in a dose-dependent manner.Isradipine pre-treatment reduces 6-hydroxydopamine induced neurotoxicity at the striatal level. Protective effect of isradipine at the striatal level is dose-dependent as shown from 6 mice. Isradipine pre-treatment increases the number of surviving SNc DA cells after 6-hydroxydopamine induced degeneration. Isradipine is capable of protecting striatal dopaminergic terminals and SNc dopaminergic cell bodies against a slow, progressive insult created by intrastriatal injection of 6-hydroxydopamine.

Isradipine has much higher (＞40 fold) affinity for Cav1.3 channels as well as good brain bioavailability. Isradipine has nearly equal potency at Cav1.2 and Cav1.3 channels.

Isradipine (0.1~3 mg/kg; p.o.) makes sodium excretion increase in a dose-dependent manner.Isradipine pre-treatment reduces 6-hydroxydopamine induced neurotoxicity at the striatal level. Protective effect of isradipine at the striatal level is dose-dependent as shown from 6 mice. Isradipine pre-treatment increases the number of surviving SNc DA cells after 6-hydroxydopamine induced degeneration. Isradipine is capable of protecting striatal dopaminergic terminals and SNc dopaminergic cell bodies against a slow, progressive insult created by intrastriatal injection of 6-hydroxydopamine. Animal Model:Rats Dosage:0.1~3 mg/kg Administration:P.o.Result:Sodium excretion increased in a dose-dependent manner. ?

PN 200-110

GPCR/G Protein

Calcium Channel

Calcium Channel

Cardiovascular Disease

——

75695-93-1

371.39

C19H21N3O5

>98% (HPLC)

Ethanol: 74 mg/mL warmed (199.25 mM); DMSO: 74 mg/mL (199.25 mM)

CC1=C(C(OC)=O)C(C2=CC=CC3=NON=C32)C(C(OC(C)C)=O)=C(C)N1

3-isopropyl 5-methyl 4-(benzo[c][1,2,5]oxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

(-20℃)

With Ice Pack

≥ 2 years